Pharma/Bio-Tech Updates: Alnylam, Baxalta, CSL Behring, Novo Nordisk
June 25, 2015; Posted by: WeBleed staff
Check out these updates from pharma/bio-tech companies Alnylam, Baxalta, CSL Behring, and Novo Nordisk.
The following organizations released updates about their company or upcoming product line. Check out the summary of each and read the original articles by clicking the links.
— Zacks.com reports that Alnylam Pharmaceuticals announced new data from its ongoing phase I study on ALN-AT3, the company’s investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the International Society on Thrombosis and Haemostasis 2015 meeting.
— The Boston Business Journal reported that Baxalta, a spin-off of Baxter International, announced early-stage trial results from its potential gene therapy treatment for hemophilia B.
— PRNewswire’s recent press release details CSL Behring at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress in Toronto, concerning data from Phase III studies evaluating the efficacy and long-term safety of its investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
— News Medical explains in this article that Novo Nordisk presented new data detailing the impact hemophilia has on both caregivers and those living with the disease at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress in Toronto.
